logo
Share SHARE
FONT-SIZE Plus   Neg

Tranzyme Pharma Says That First Phase 3 Pivotal Trial Of Ulimorelin Failed

Late-stage biopharmaceutical company Tranzyme Pharma (TZYM), on Monday, along with specialty pharmaceutical company Norgine B.V., announced top-line results of the primary analysis of ULISES 007, the first of two Phase 3 pivotal trials evaluating ulimorelin.

The company stated that the trial failed to meet its primary and secondary efficacy endpoints.

Tranzyme further stated that the results of ULISES 007 showed that ulimorelin, at both 160 and 480 micrograms/kg doses, was not statistically different from placebo for the primary endpoint.

"These results are surprising and disappointing. While we are still planning to analyze the data from the second phase 3 trial ULISES 008, which we expect by the end of the second quarter, we are stopping all other NDA activities for ulimorelin," said Vipin K. Garg, Ph.D., President and Chief Executive Officer, Tranzyme Pharma.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Hennes & Mauritz AB or H&M were plunging around 13 percent in Sweden after the retailer reported lower sales in its fourth quarter with weakness in H&M brand's physical stores. However, H&M brand's online sales and sales of the group's other brands continued to develop well, the company said. We urge investors to take advantage of the weakness in shares of Ichor Holdings, Ltd. (ICHR), because we believe the company's 2017 acquisitions bode well for the stock. ICHR is more than 30% off its recent 52-week, intra-day high, and this pullback in the absence of any sharp change in fundamentals, positions the stock for at least 20% potential upside from current levels. French aircraft maker Dassault Aviation SA said Wednesday that following repeated delays, it has terminated a contract with French defense company Safran for its Silvercrest engine that was intended to power Dassault's Falcon 5X business jet.
comments powered by Disqus
Follow RTT